| 主权项 |
1. A method of inhibiting fatty acid synthase (FASN) in a subject, wherein the subject has a FASN-mediated disorder selected from hyperproliferative disorders, inflammatory disorders, obesity related disorders, Type II diabetes mellitus, fatty liver disease, microbial infections, viral infections, bacterial infections, fungal infections, parasitic infections, and protozoal infections comprising administering to a subject a therapeutically effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, tautomer, stereoisomer and/or polymorph thereof; wherein: RA is selected from C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl and 5-14 membered heteroaryl; RB is selected from C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, 3-14 membered heterocyclyl, C6-14 aryl and 5-14 membered heteroaryl; RC is selected from hydrogen, —OH, —ORC1, —ON(RC2)2, —N(RC2)2, —C(═O)RC1, —CHO, —CO2RC1, —C(═O)N(RC2)2, —C(═NRC2)ORC1, —C(═NRC2)N(RC2)2, —SO2RC1, —S(═O)RC1, —Si(RC1)3, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl; each instance of RC1 is, independently, selected from C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl; and each instance of RC2 is, independently, selected from hydrogen, —OH, —ORC1, —CN, —C(═O)RC1, —CO2RC1, —SO2RC1, —P(═O)2RC1, —P(═O)(RC1)2, C1-10 alkyl, C1-10 perhaloalkyl, C2-10 alkenyl, C2-10 alkynyl, 3-14 membered heteroaliphatic, C3-10 carbocyclyl, 3-14 membered heterocyclyl, C6-14 aryl, and 5-14 membered heteroaryl, or two RC2 groups are joined to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring; or RB and RC together with the nitrogen (N) atom to which each is attached are joined to form a 5-14 membered ring. |
